Tempus AI shares moved lower in Tuesday trading, a drift that lines up with pre-earnings positioning as the company is scheduled to report first-quarter 2026 financial results after the market close on May 5, 2026. With a high-beta, growth-healthcare profile, the name tends to see volatility compress or reverse into results as investors trim exposure and options hedging increases into the event.

A recent Form 4 filing showing insider sales under a 10b5-1 plan has added an overhang for near-term sentiment, even when sales are pre-planned. The disclosure can matter into earnings because it reinforces the idea that supply may be hitting the market while investors wait for proof points on revenue growth durability and the path to profitability.

The stock’s next directional catalyst is the Q1 report and management commentary tonight. Investors will likely key in on revenue trajectory versus expectations, demand signals across diagnostics and data businesses, and any updates to full-year outlook and margin progression that could reset near-term valuation multiples.